TGA investigates bowel obstruction risk with semaglutide
The US medicine regulator updated the product information for Ozempic last month to include a warning about potential risk of ileus.
The TGA is investigating reports of intestinal obstruction in patients using semaglutide and may consider updating the product information to include a warning about ileus.
The watchdog said it had received four reports of adverse gastrointestinal events linked with semaglutide (Ozempic) to date.
